Floatz logo

IANALUMAB

Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma

Novartis Pharmaceuticalsmonoclonal_antibodyPhase 1Active
D
23/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
8/ 100
Competitive Position
95/ 100

Competitive context

410 Active assets in the Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
Memorial Sloan Kettering Cancer Center
Phase 3BBB
PEGASPARGASE
Ciusss de L'Est de l'Île de Montréal
Phase 4BBB
Inno-206
National Cancer Institute (NCI)
Phase 4BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Mwanasha Merrill, MD
Phase 3BBB
Entecavir
Fudan University
Phase 4BBB

View all 50 →

Same molecule, other indications

IANALUMAB is also rated in:

relapsing-remitting multiple sclerosisDormant
D
Indicative ·
29 / 100
View asset →
idiopathic pulmonary fibrosisDormant
D
Indicative ·
29 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
D
Indicative ·
23 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →